1. Generics Bulletin
  2. >>Business

Sandoz Aims To Be ‘First In And Last Out’ In North America

New Regional Head Keren Haruvi Lays Out Strategy In US And Canada

 
• By Dave Wallace

Sandoz is determined to be “first in and last out” on key product opportunities, while also seeking to strengthen its pipeline through deals and partnerships, the company’s new North America head, Keren Haruvi, tells Generics Bulletin in an exclusive interview.

North America Globe Earth
Keren Haruvi recently took over as Sandoz' head of North America • Source: Shutterstock

At the start of 2021, Sandoz performed a major reshuffle of its management in North America that saw regional head Carol Lynch move on to become the Novartis unit’s global chief business officer. At the same time, former Novartis head of mergers and acquisitions, Keren Haruvi, took over as president of Sandoz US and head of North America for the generics giant. (Also see "Haruvi Takes Charge Of Sandoz North America" - Generics Bulletin, 14 January, 2021.)

A couple of months on from her appointment, Haruvi has talked to Generics Bulletin about how Sandoz is seeking to position itself as “first in” to new product markets while also aiming to be “last out” through cost competitiveness and supply stability; how the firm is planning to bolster its pipeline through business development and licensing

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business

‘I’ll Be Happy When We Have 40-Plus Assets’ – Sandoz Builds Up Biosimilars

 
• By Dave Wallace

With biosimilars playing an increasingly important role in Sandoz’s business, the firm’s first-quarter results call saw management lay out the latest key developments. Meanwhile, the company also addressed the issue of US tariffs, voicing optimism over both future developments as well as its ability to weather current measures.

Teva To Slash Thousands Of Jobs And Shut More Sites Under $700m Savings Plan

 
• By Dean Rudge

Teva’s plans to generate net savings of $700m by 2027 have been described by the firm as a journey and not a destination, with the suggestion that “this era of cost efficiency, harmonization, frugality will continue.”

Tetris Deal Falls Into Place For UK’s Aspire

 
• By Dave Wallace

Niche generics company Aspire Pharma has struck a deal to acquire a portfolio of products from fellow UK firm Tetris Pharma as it is wound up, paying Tetris parent Arecor £0.5m for UK distribution rights and inventory.